TWIRLA (Ethinyl Estradiol; Levonorgestrel) Patent Expiration, LOE Window & CMS Spending

TWIRLA (Ethinyl Estradiol; Levonorgestrel) by Agile Therapeutics: FDA Orange Book core substance LOE 2028-08-26, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAgile Therapeutics
FDA Application & PathwayN204017 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2028-08-26
Last Listed Patent or Exclusivity Date2028-08-26
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 28.1% 2-yr change)